A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy
This study will evaluate the efficacy and safety of single-agent MLN0128 and the combination
of MLN0128 + MLN1117 compared with everolimus in the treatment of participants with
metastatic clear-cell renal cell carcinoma (mccRCC) that have progressed on vascular
endothelial growth factor (VEGF)-targeted therapy.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society